In this first cost-efficiency and expanded access study of biosimilar rituximab in DLBCL in Medicare, we find that conversion to biosimilar-based R-CHOP can result in substantial cost savings relative to originator-based R-CHOP. These biosimilar-associated cost savings could be reinvested to treat thousands of additional DLBCL patients or fund other costs of care in Medicare, on a budget-neutral basis.
Roth et al. (2026) studied this question.